Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Dexamethasone Sodium Phosphate
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : AVM0703 is small molecule immunomodulatory drug enrolling Phase 2 trials in US in relapsed/refractory Non-Hodgkin's Lymphoma (NHL) which began enrollment Q3 2023 (partially funded by NCI Ph II FastTrak grant 1R44CA272096).
Brand Name : AVM0703
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 01, 2023
Lead Product(s) : Dexamethasone Sodium Phosphate
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Dexamethasone Sodium Phosphate
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : National Cancer Institute
Deal Size : $2.0 million
Deal Type : Funding
Details : AVM0703 (Dexamethasone sodium phosphate) is a small molecule which triggers the production and release of endogenous bispecific gamma delta TCR+ invariant TCR+ Natural Killer T-like cells (AVM-NKT).
Brand Name : AVM0703
Molecule Type : Small molecule
Upfront Cash : Undisclosed
June 14, 2022
Lead Product(s) : Dexamethasone Sodium Phosphate
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : National Cancer Institute
Deal Size : $2.0 million
Deal Type : Funding
Lead Product(s) : Dexamethasone Sodium Phosphate
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : AVM0703 (dexamethasone) led to, complete response in 27% of immune-resistant mouse A20 tumors as monotherapy and complete response in 60% when combined with 2 doses of cyclophosphamide/fludarabine (CyFlu).
Brand Name : AVM0703
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 01, 2022
Lead Product(s) : Dexamethasone Sodium Phosphate
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Dexamethasone
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : AVM0703 is a small molecule which triggers the production and release of endogenous bispecific gamma delta TCR+ and invariant TCR+ Natural Killer T-like cells (AVM-NKT).
Brand Name : AVM0703
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 19, 2022
Lead Product(s) : Dexamethasone
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Dexamethasone
Therapeutic Area : Endocrinology
Study Phase : Preclinical
Sponsor : National Institute of Diabetes and Digestive Kidney Disease
Deal Size : $1.6 million
Deal Type : Funding
Details : T1D is an autoimmune disease that destroys beta cells, the insulin-making cells in the pancreas. This award provides an endorsement of AVM0703’s potential in two distinct and crucial therapeutic areas, diabetes and cancer.
Brand Name : AVM0703
Molecule Type : Small molecule
Upfront Cash : Undisclosed
April 05, 2022
Lead Product(s) : Dexamethasone
Therapeutic Area : Endocrinology
Highest Development Status : Preclinical
Sponsor : National Institute of Diabetes and Digestive Kidney Disease
Deal Size : $1.6 million
Deal Type : Funding
Lead Product(s) : Dexamethasone Sodium Phosphate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Seattle AVM Biotechnology Announces Second IND for AVM0703
Details : This second study will evaluate AVM0703 in two different ARDS patient populations: one with COVID-19-mediated moderate to severe ARDS and the other with Influenza-mediated severe ARDS.
Brand Name : AVM0703
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 16, 2020
Lead Product(s) : Dexamethasone Sodium Phosphate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Dexamethasone Sodium Phosphate,Hydrocortisone,Undisclosed
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
AVM Biotechnology Awarded SBIR Phase I Grant from National Cancer Institute
Details : AVM Biotechnology has been awarded a National Cancer Institute Small Business Innovation Research Grant from the NIH to study the use of AVM0703 as a preconditioning agent to allow safe and efficient delivery of therapeutic immune cells for cancer treatm...
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 11, 2020
Lead Product(s) : Dexamethasone Sodium Phosphate,Hydrocortisone,Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Dexamethasone Sodium Phosphate
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
AVM Biotechnology has FDA Approval for Clinical Trials for Promising New Cancer Treatment
Details : AVM Biotechnology received clinical trial approval for AVM0703. Unlike chemotherapy and radiation, AVM0703 spares platelets and red blood cells, limiting the need for transfusions.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 14, 2020
Lead Product(s) : Dexamethasone Sodium Phosphate
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?